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Relation ofbirth variables to
death from cardiovascular
disease
EDITOR,-D J P Barker and colleagues' study puts
a further nail in the coffin of those who doubt
that the intrauterine environment influences later
health-in this instance, death from cardiovas-
cular disease.' A theme running through the
Southampton group's many studies on this topic is
that maternal nutrition is primarily responsible for
reduced prenatal growth. Though there can be no
doubting the importance of maternal malnutrition
as a cause of reduced fetal growth in poor countries
and even perhaps in Preston, Sheffield, and Hert-
ford in the early part of this century, where Barker
and colleagues' cohorts were born and brought
up, there is no strong evidence of undernutrition
now being responsible for restraining intrauterine
growth in developed countries.
Maternal diet is only one of the many factors that
can lead to fetal growth retardation. To begin
to understand mechanisms that might link the
environment of fetal life and infancy with later
disease, influences other than maternal nutrition
need to be considered-for example, Edwards et al
have recently proposed that links between the fetal
environment, adult hypertension, and low birth
weight could be mediated through dysfunction of
the placental barrier to maternal cortisol.2
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Paradoxical pain
EDITOR,-David Bowsher defines paradoxical
pain as chronic nociceptive pain that does not
respond to morphine.' It is more generally under-
stood as pain that is made worse rather than better
by increasing doses of morphine. It has been
reliably reported with large doses of intrathecal
morphine and diamorphine and probably occurs
occasionally with large daily doses of the same
drugs intravenously. Bowsher and his colleagues
have made a good case for paradoxical pain being
the result of a genetic inability to metabolise
morphine to the potent morphine 6-glucuronide,2
leaving large quantities of morphine 3-glucuro-
nide (a putative morphine antagonist or a non-
specific cerebral stimulant, or both' 4) unopposed.
It is difficult, therefore, to understand why
Bowsher has opted for an alternative definition.
It is also disturbing that he has used "over-
whelming pain" as a synonym for paradoxical pain.
Overwhelming pain is a term used to emphasise a
common result of chronic unrelieved severe cancer
pain.5 It almost always responds to adequate
amounts of morphine, coanalgesics if appropriate,
and, usually, an anxiolytic. A comparable situation
is sometimes seen despite large doses of morphine
when the patient's anxieties and fears have not
been addressed. Thus, in one case, a patient
with inoperable cancer of the oesophagus was still
in pain despite receiving 12 g of oral morphine a
day when he was admitted to a hospice; a week
later he was free of pain when taking 60 mg of
morphine a day and 10 mg of diazepam at night.
His seemingly morphine resistant nociceptive
cancer pain responded to listening, explanation,
and the setting of positive rehabilitation goals.
Nociceptive pain is also relatively resistant to
morphine and other opioids when there is peri-
pheral or central neural sensitisation. Sensitisation
occurs in damaged tissue and the surrounding
area and in areas subserved by either an injured
peripheral nerve or an injured part of the central
nervous system. Pain associated with inflammation
is a typical example of peripheral sensitisation,5
hence the need to use a non-steroidal anti-inflam-
matory drug in most patients with painful soft
tissue and bone metastases. Morphine alone is
often inadequate, but there is nothing paradoxical
about this. Central sensitisation may also occur in
such cases as part of a secondary "wind up"
phenomenon in the dorsal horn. Occasionally
this requires specific correction-for example,
with an N-methyl-D-aspartate receptor blocker
such as ketamine.75 Central sensitisation in neuro-
pathic pain is possibly more complex and, as
Bowsher points out, demands a range of alternative
measures.9 '0
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EDITOR,-Paradoxical pain is a new and confusing
term that has been defined in different ways. David
Bowsher decribes it as nociceptive pain that is not
receptive (does he mean responsive?) to opioids.'
Yet in an earlier publication, in which the term was
first coined, he and his colleagues used it to
describe "pain [which] ceases to be relieved or is
worsened by further administration" of morphine
or diamorphine (our italics).' We have not seen any
patients whose physical pain has been made worse
by morphine or diamorphine, nor are we aware
of any good evidence that this occurs. More
importantly, we fear that the suggestion that this
may happen may deter some doctors from giving
adequate doses of these drugs when they are
properly indicated.
It is well recognised that opioid analgesics
do not always relieve pain, and there are already
several unsatisfactory ways in which such pain is
described, including "opioid insensitive," "opioid
non-responsive," and "opioid resistant." As we
have written elsewhere, these terms have subtle
differences in meaning, which are partly semantic
but partly reflect different views.' The introduc-
tion of yet another term will add confusion. We
believe that what has been described as paradoxical
pain is what we would refer to as "opioid poorly
responsive" pain and that opioid responsiveness
is a continuum that may be influenced by any
of a large number of factors related to the patient
and the drug as well as the pain. The pharmaco-
kinetics of morphine may provide at least part
of the explanation, but there are too few data
to justify the editorial's subheading (morphine 3-
glucuronide does not, by the way, bind to opiate
receptors).
In 1967 Cicely Saunders described the concept
of total pain, which encompasses the psychological,
emotional, and spiritual turmoil of some patients
with severe pain. Might this be what Bowsher
refers to as overwhelming pain?
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EDITOR,-David Bowsher's editorial oversimpli-
fies a complex and contentious issue.' Paradoxical
pain may well exist but is neither well documented
nor common; it does not account for the majority
of cases of uncontrolled pain, and we are not aware
of any evidence that it was an important factor
in the care of the patient in the recent highly
publicised court case.2
The hypothesis that paradoxical pain is caused
by abnormal metabolism of morphine is plausible
but built on shaky foundations. The evidence in
rats that morphine 3-glucuronide may antagonise
the analgesic actions of morphine'4 is unsubstan-
tiated and is hard to explain given that morphine
3-glucuronide has a much lower binding affinity for
opioid receptors than either morphine or the active
morphine metabolite, morphine 6-glucuronide.5"
Furthermore, large interspecies variations exist
not only in the metabolism of morphine but also in
the distribution of opioid receptors.78 Thus animal
data on this subject cannot, and should not, be
extrapolated to humans and many questions
remain.
Though recognition of this potential therapeutic
problem is welcome, until the clinical importance
of the morphine metabolites in humans is com-
pletely understood these rare cases of paradoxical
pain will remain unexplained.
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EDITOR,-The concept of paradoxical pain and its
relation to morphine metabolites raises many
questions.' There are several conceptual errors
inherent in this description. One of the most
fundamental is that the pain syndromes as des-
cribed should at any time actually respond to
opioids. This makes the assumption that so called
paradoxical pain is nociceptive pain, with the
second assumption that all nociceptive pain
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